Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 4, 2008, Pages 411-417

  Stroescu, Cezar ^a   Dragnea, Adrian ^b   Ivanov, Bogdan ^a   Pechianu, Catalin ^a   Herlea, Vlad ^a   Sgarbura, Olivia ^a   Popescu, Andra ^a   Popescu, Irinel ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b General Department   (Romania)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; p53; PCNA; Prognosis; VEGF

Indexed keywords

CYCLINE; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LIVER CELL CARCINOMA; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; KI-67 ANTIGEN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67149138036     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Li GH, Li JQ. Subclinical primary liver carcinoma. J Surg Oncol 1989; 42: 181-183.
2. Tang ZY. Subclinical hepatocellular carcinoma. Zhonghua Zhong. Liu Za Zhi 1983;5: 226-228.
3. Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis. Cancer 1990; 65: 1104-1110.
4. Nakashima T, Kojiro M. Pathology of hepatocellular carcinoma. Nippon Geka Gakkai Zasshi 1983; 84: 939-942.
5. Yuki K, Hirohashi S, Sakamoto M, Kanai T, Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer 1990; 66: 2174-2179.
6. Herlea V, Paslaru L, Popescu I. Identification of programmed cell death (apoptosis) and cell proliferation in human cholangiocarcinoma and hepatocellular Carcinoma. Rom J Gastroenterol 2001; 10: 279-284.
7. Li JQ, Zhang YQ, Zhang WZ. Evaluation of chemoembolization as an adjuvant therapy for primary liver carcinoma after surgical resection. Zhonghua Zhong Liu Za Zhi 1994; 16: 387-389.
8. Kitamoto M, Nakanishi T, Kira S, et al. The assessment of proliferating cell nuclear antigen immunohistochemical staining in small hepatocellular carcinoma and its relationship to histologic characteristics and prognosis. Cancer 1993; 72: 1859-1865.
9. Itoh T, Shiro T, Seki T. The clinicopathological study of p53 overexpression in hepatocellular carcinoma. Acta Hepatol Jpn 1993; 34: 989-994.
10. Li JQ, Zhang CQ, Zhang YQ, Yuan YF, Chen MS, Li GH. Immunohistochemical study of PCNA and p53 in primary liver aancer - an implication for prognosis and treatment. J Exp Clin Cancer Res 1996; 15: 77-80.
11. Ng IO, Chung LP, Tsang SW et al. P53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 1994; 9: 985-990.
12. Hsu HC, Tseng HJ, Lai PL, Lee PH, Peng SY. Expression of p53 Gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res 1993; 53: 4691-4694.
13. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705-708.
14. Feng KT, Zhang CQ, Zhang JX, Zhong YS. A new immunohistochemical staining methods for p53 protein. Chin J Diagnos Pathol 1994; 1: 1-50.
15. Dumont DJ, Gradwohl G, Fong GH, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897-1909.
16. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999; 155: 1967-1976.
17. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-1466.
18. Saftoiu A, Ciurea T, Georgescu C et al. Immunohistochemical assessment of proliferating cell nuclear antigen in primary hepatocellular carcinoma and dysplastic nodules. J Cell Mol Med 2003; 7: 436-446.
19. de La Coste A, Mignon A, Fabre M, et al. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res 1999; 59: 5017-5022.
20. Brodsky SV, Mendelev N, Melamed M, Ramaswamy G. Vascular density and VEGF expression in hepatic lesions. J Gastrointestin Liver Dis 2007; 16: 373-377.
21. Thelen A, Scholz A, Benckert C, et al. VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma. Int J Cancer 2008; 122: 2471-2481.
22. Ferrero S, Ragni N. Prognostic value of plasma and serum VEGF levels in patients with resectable hepatocellular carcinoma. Ann Surg Oncol 2003; 10: 1123.
23. Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33: 376-382.
24. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
25. Maeda MY, Simoes M, Wakamatsu A, et al. Relevance of the rates of PCNA, Ki-67 and p53 expression according to the epithelial compartment in cervical lesions. Pathologica 2001; 93: 189-195.
26. Jaskulski D, deRiel JK, Mercer WE, Calabretta B, Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988; 240: 1544-1546.
27. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science 1990; 249: 1046-1049.